MMJ International Holdings Corp.
MMJ has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
MMJ is successfully developing several prescription medications derived from the cannabis plant for the treatment of spasticity and chorea due to multiple sclerosis and Huntington’s disease.
The company has a pipeline of additional clinical stage cannabinoid and other natural botanical product candidates for both orphan and non-orphan indications with a specific focus on neurological conditions.
MMJ was founded in 2015 and is privately owned. The company has operations in both the US and Jamaica.
The company’s founder Duane Boise is a well-known business entrepreneur who has a passion for helping patients with serious unmet medical needs. He is intent on doing this with medicines which have the potential to make a real difference in lives of others.
Following its inception, MMJ is positioned to commenced its first clinical trials evaluating different cannabinoid formulations as potential therapeutics with an initial focus on the development of an gel cap formulation with two principal cannabinoid components, cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC).
Working with leading cannabinoid scientists around the world, MMJ is continuing to explore the potential of a range of novel cannabinoid and other botanical molecules in a number of distinct therapeutic areas.
MMJ’s lead product candidate, is a liquid formulation of highly purified CBD/THC being investigated for severe neurological disorders. This product is the result of extensive research. MMJ will commence an orphan clinical program in Multiple Sclerosis and Huntington’s disease to treat forms of spasticity and chorea.
MMJ has submitted several Investigational New Drug Applications with the FDA. MMJ has been awarded Orphan Drug Designation from the FDA for Huntington’s disease diseases. Additionally, MMJ anticipates it will receive Fast Track Designation from the FDA for its clinical trials.
MMJ’s focus is to bring novel natural botanical plant and cannabinoid-based prescription medicines. Through the combination of rapid cost-effective product development that addresses these unmet needs, MMJ seeks to maximize the value of its product development opportunities and shareholder returns.
MMJ’s strategy is to become a market leader in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. MMJ has developed an extensive international team of prominent scientists in the cannabinoid field as well as plant-based prescription pharmaceutical product formulation experience. MMJ manufactures its prescription pharmaceutical products to meet the stringent GMP requirements of the U.S. FDA, DEA and other global regulatory authorities. MMJ establishes controls over all facets of product development, manufacturing and commercial distribution.